San Diego, CA, United States of America

Sujin Cho-Schultz

USPTO Granted Patents = 5 

 

 

Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Sujin Cho-Schultz

Introduction

Sujin Cho-Schultz is a prominent inventor based in San Diego, California. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological pathways. With a total of five patents to her name, her work has the potential to impact various therapeutic areas.

Latest Patents

Among her latest patents are innovative compounds such as Cyclin dependent kinase inhibitors, which relate to compounds of Formula (I). Additionally, she has developed Azalactam compounds as HPK1 inhibitors, which pertain to compounds of general Formula I. These inventions showcase her expertise in medicinal chemistry and her commitment to advancing healthcare solutions.

Career Highlights

Sujin Cho-Schultz currently works at Pfizer Corporation, a leading global biopharmaceutical company. Her role involves research and development, where she applies her knowledge to create new therapeutic options. Her contributions have been recognized within the industry, and she continues to be a driving force in her field.

Collaborations

Throughout her career, Sujin has collaborated with talented professionals, including Sajiv Krishnan Nair and Mehran Jalaie. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new therapies.

Conclusion

Sujin Cho-Schultz exemplifies the spirit of innovation in the pharmaceutical industry. Her patents and collaborative efforts contribute to the advancement of medical science, making her a notable figure in her field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…